The clinical effectiveness and cost-effectiveness of topotecan for small cell lung cancer: a systematic review and economic evaluation
Loveman E, Jones J, Hartwell D, Bird A, Harris P, Welch K, Clegg A
Record ID 32010000110
English
Authors' recommendations:
Review found that, as a second-line treatment for patients with relapsed small cell lung cancer, topotecan is better than best supportive care in terms of improved survival. Treatment with oral topotecan may be cost-effective compared with best supportive care
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1754
Year Published:
2010
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Small Cell Lung Carcinoma
- Topotecan
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2010 Queen’s Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.